/

XAIR

Beyond Air, Inc.Closed

2.19−0.14 −6.01%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 2.19 −0.01%

Open

2.35

Prev close

2.33

Day range

2.162.37

52-week range

2.1655.00

Volume

35.70K0.16×

Mkt cap

2.16M

P/E ttm

—

Fwd P/E

-1.32

EPS ttm

-64.40

Div yield

0.00%

Earnings

Aug 13, 2026

From 52w high

−96.02%

Price Chart

Yahoo Finance · delayed

XAIROct 13, 2026O 2.35H 2.37L 2.16C 2.19−0.12 (−5.19%)Vol 35.70K

SMA 503.96
SMA 20011.62

1Y change −95.84% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

XAIR Beyond Air, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −14.12%
1 month: −31.56%
3 months: −62.05%
6 months: −80.79%
Year to date: −84.92%
1 year: −95.84%

Valuation & ownership

Market cap: 2.16M
Enterprise value: 16.73M
P/E (ttm): —
Forward P/E: -1.32
PEG ratio: —
Price / book: 0.82
Price / sales (ttm): 0.28
EV / EBITDA: -0.68
EPS (ttm): -64.40
EPS (forward): -1.66
Beta (5y monthly): 0.21
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 984.41K
Float: 764.20K
Short % of float: 6.46%
Short ratio (days): 0.13
Held by insiders: 22.38%
Held by institutions: 7.00%
Avg volume (3m): 224.92K
50-day average: 4.04
200-day average: 11.69
52-week change: −95.84%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 28.3
vs 50-day SMA: −44.70%
vs 200-day SMA: −81.15%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 13.34%
Realised vol (20d, ann.): 89.1%
From 52-week high: −96.02%
From 52-week low: +1.39%

ANR

Analyst Consensus

2 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

20.00

+813.24% implied

Low 10.00Median 20.00High 30.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0

DES

About Beyond Air, Inc.

Yahoo Finance profile

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Sector: Healthcare
Industry: Medical Devices
Employees: 54
Headquarters: Garden City, NY, United States
Website: beyondair.net
Officers: Mr. Robert Scott Goodman CEO & Director
Mr. Daniel J. Moorhead CPA Chief Financial Officer

SEAS

Seasonality · XAIR

2018–2026 · monthly returns

Strongest month Feb +5.79%Weakest month Apr −12.45%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	63.9	-19.2	-28.2	-23.9	-12.4	-3.0	-40.9	-24.7	-30.5	-20.7			−84.9%
2025	6.7	-29.5	1.1	-28.6	-6.7	-5.5	-13.4	-25.5	4.1	-10.8	-34.5	-46.2	−89.9%
2024	-14.3	22.0	-15.1	-37.9	18.5	-58.0	8.0	-23.8	-12.2	46.9	-9.6	-30.3	−81.7%
2023	0.9	-7.0	10.8	-13.6	-9.8	-19.0	-15.3	-15.7	-24.1	0.9	-32.2	24.1	−69.8%
2022	-27.0	15.5	-16.1	-10.8	-4.2	17.2	38.0	1.6	-20.7	-8.7	-15.6	13.3	−31.3%
2021	12.3	0.2	-7.3	11.6	-19.4	30.9	21.6	39.6	1.1	-7.6	41.2	-34.9	+79.1%
2020	12.8	40.3	-3.4	-7.9	-1.2	-0.4	-14.3	-10.6	-6.5	1.0	1.9	-1.3	+0.8%
2019	6.5	-1.0	-2.0	0.0	7.3	7.8	-9.4	-1.6	-7.1	-6.5	15.1	5.7	+12.5%
2018							4.3	-0.3	21.2	-2.3	-18.8	34.8	+34.8%

INSD

Insider Activity · XAIR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 20, 2025	Lisi Steven AChief Executive Officer	Purchase at price 3.25 per share.	6K	$19.49K
Mar 13, 2025	Carey Robert F.Director	Purchase at price 0.25 - 0.26 per share.	1.00M	$250.05K
Feb 18, 2025	Gaul Michael AChief Operating Officer	Purchase at price 0.38 per share.	6K	$2.29K
Sep 25, 2024	Carey Robert F.Director	Purchase at price 0.50 per share.	1.48M	$744.66K
Sep 25, 2024	Lisi Steven AChief Executive Officer	Purchase at price 0.50 per share.	1.48M	$744.66K
Aug 14, 2024	Lisi Steven AChief Executive Officer	Purchase at price 0.37 per share.	50K	$18.34K
Aug 13, 2024	Carey Robert F.Director	Purchase at price 0.40 per share.	100K	$39.68K
Aug 13, 2024	Lucera Erick J.Director	Purchase at price 0.40 per share.	39.3K	$15.56K
Aug 13, 2024	Lisi Steven AChief Executive Officer	Purchase at price 0.39 per share.	100K	$38.64K

XAIR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

XAIR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Beyond Air, Inc.

Seasonality · XAIR

Insider Activity · XAIR

Congress Trades · XAIR

Investors Holding XAIR

Investors Holding XAIR

Congress Trades · XAIR

Insider Activity · XAIR

Seasonality · XAIR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Beyond Air, Inc.

Financial Snapshot

Earnings & Dividends

News